Arbutus Biopharma Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABUS research report →
About the company
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.
- CEO
- Lindsay Androski
- IPO
- 2007
- Employees
- 19
- HQ
- Warminster, PA, US
Price Chart
- Market Cap
- $962.01M
- P/E
- 5.87
- P/S
- 5.02
- P/B
- 3.63
- EV/EBITDA
- 5.84
- Div Yield
- 0.00%
- Gross Margin
- 99.98%
- Op Margin
- 80.79%
- Net Margin
- 83.95%
- ROE
- 129.32%
- ROIC
- 56.72%
- Revenue
- $14.08M · 128.21%
- Net Income
- $-33,501,000 · 52.09%
- EPS
- $-0.17 · 55.26%
- Op Income
- $-27,051,000
- FCF YoY
- 39.05%
- 52W High
- $5.10
- 52W Low
- $3.08
- 50D MA
- $4.39
- 200D MA
- $4.42
- Beta
- 0.62
- Avg Volume
- 2.00M
Get TickerSpark's AI analysis on ABUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 26 | Sawhney Roger | other | 78,800 |
| Jun 8, 26 | Beardsley Robert A | other | 78,800 |
| Feb 2, 26 | Nguyen Tuan | other | 188,400 |
| Feb 2, 26 | Nguyen Tuan | other | 73,500 |
| Feb 2, 26 | Androski Lindsay | other | 71,700 |
| Feb 2, 26 | Androski Lindsay | other | 28,000 |
| Aug 4, 25 | Sawhney Roger | other | 157,600 |
| Aug 4, 25 | Sawhney Roger | other | 0 |
| Mar 31, 25 | Nguyen Tuan | other | 750,000 |
| Mar 31, 25 | Nguyen Tuan | other | 750,000 |
Our ABUS coverage
Recent articles, reports, and earnings notes.
No research on ABUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABUS report →Similar companies
Peers in the same neighborhood.